--- provider: falcon model: Edison Scientific Literature cached: false start_time: '2026-06-03T09:43:51.515896' end_time: '2026-06-03T09:50:59.432835' duration_seconds: 427.92 template_file: templates/gene_research_go_focused.md template_variables: organism: human gene_id: AFG3L2 gene_symbol: AFG3L2 uniprot_accession: Q9Y4W6 protein_description: 'RecName: Full=Mitochondrial inner membrane m-AAA protease component AFG3L2 {ECO:0000305}; EC=3.4.24.- {ECO:0000269|PubMed:14623864, ECO:0000269|PubMed:19748354, ECO:0000269|PubMed:22354088, ECO:0000269|PubMed:29932645, ECO:0000269|PubMed:31327635, ECO:0000269|PubMed:37917749, ECO:0000269|PubMed:38157846}; EC=3.6.-.- {ECO:0000269|PubMed:19748354, ECO:0000269|PubMed:31327635}; AltName: Full=AFG3-like protein 2 {ECO:0000305}; AltName: Full=Paraplegin-like protein; Flags: Precursor;' gene_info: Name=AFG3L2 {ECO:0000303|PubMed:10395799, ECO:0000312|HGNC:HGNC:315}; organism_full: Homo sapiens (Human). protein_family: In the C-terminal section; belongs to the peptidase M41 protein_domains: AAA+_ATPase. (IPR003593); AAA_lid_3. (IPR041569); ATP-dep_Zn_Metalloprotease. (IPR050928); ATPase_AAA_core. (IPR003959); ATPase_AAA_CS. (IPR003960) provider_config: timeout: null max_retries: 3 parameters: allowed_domains: [] temperature: 0.1 max_embedded_images: 8 citation_count: 25 artifact_count: 1 artifact_sources: edison_answer_artifacts: 1 artifacts: - filename: artifact-00.md path: AFG3L2-deep-research-falcon_artifacts/artifact-00.md media_type: text/markdown source: edison_answer_artifacts data_storage_id: null description: Edison artifact artifact-00 --- ## Question # Gene Research for Functional Annotation ## ⚠️ CRITICAL: Gene/Protein Identification Context **BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms. ### Target Gene/Protein Identity (from UniProt): - **UniProt Accession:** Q9Y4W6 - **Protein Description:** RecName: Full=Mitochondrial inner membrane m-AAA protease component AFG3L2 {ECO:0000305}; EC=3.4.24.- {ECO:0000269|PubMed:14623864, ECO:0000269|PubMed:19748354, ECO:0000269|PubMed:22354088, ECO:0000269|PubMed:29932645, ECO:0000269|PubMed:31327635, ECO:0000269|PubMed:37917749, ECO:0000269|PubMed:38157846}; EC=3.6.-.- {ECO:0000269|PubMed:19748354, ECO:0000269|PubMed:31327635}; AltName: Full=AFG3-like protein 2 {ECO:0000305}; AltName: Full=Paraplegin-like protein; Flags: Precursor; - **Gene Information:** Name=AFG3L2 {ECO:0000303|PubMed:10395799, ECO:0000312|HGNC:HGNC:315}; - **Organism (full):** Homo sapiens (Human). - **Protein Family:** In the C-terminal section; belongs to the peptidase M41 - **Key Domains:** AAA+_ATPase. (IPR003593); AAA_lid_3. (IPR041569); ATP-dep_Zn_Metalloprotease. (IPR050928); ATPase_AAA_core. (IPR003959); ATPase_AAA_CS. (IPR003960) ### MANDATORY VERIFICATION STEPS: 1. **Check if the gene symbol "AFG3L2" matches the protein description above** 2. **Verify the organism is correct:** Homo sapiens (Human). 3. **Check if protein family/domains align with what you find in literature** 4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP** ### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature: **DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead: - State clearly: "The gene symbol 'AFG3L2' is ambiguous or literature is limited for this specific protein" - Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism") - Describe the protein based ONLY on the UniProt information provided above - Suggest that the protein function can be inferred from domain/family information ### Research Target: Please provide a comprehensive research report on the gene **AFG3L2** (gene ID: AFG3L2, UniProt: Q9Y4W6) in human. The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims. You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway. We are interested in where in or outside the cell the gene product carries out its function. We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role. Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available. ## Output Question: You are an expert researcher providing comprehensive, well-cited information. Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims. # Gene Research for Functional Annotation ## ⚠️ CRITICAL: Gene/Protein Identification Context **BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms. ### Target Gene/Protein Identity (from UniProt): - **UniProt Accession:** Q9Y4W6 - **Protein Description:** RecName: Full=Mitochondrial inner membrane m-AAA protease component AFG3L2 {ECO:0000305}; EC=3.4.24.- {ECO:0000269|PubMed:14623864, ECO:0000269|PubMed:19748354, ECO:0000269|PubMed:22354088, ECO:0000269|PubMed:29932645, ECO:0000269|PubMed:31327635, ECO:0000269|PubMed:37917749, ECO:0000269|PubMed:38157846}; EC=3.6.-.- {ECO:0000269|PubMed:19748354, ECO:0000269|PubMed:31327635}; AltName: Full=AFG3-like protein 2 {ECO:0000305}; AltName: Full=Paraplegin-like protein; Flags: Precursor; - **Gene Information:** Name=AFG3L2 {ECO:0000303|PubMed:10395799, ECO:0000312|HGNC:HGNC:315}; - **Organism (full):** Homo sapiens (Human). - **Protein Family:** In the C-terminal section; belongs to the peptidase M41 - **Key Domains:** AAA+_ATPase. (IPR003593); AAA_lid_3. (IPR041569); ATP-dep_Zn_Metalloprotease. (IPR050928); ATPase_AAA_core. (IPR003959); ATPase_AAA_CS. (IPR003960) ### MANDATORY VERIFICATION STEPS: 1. **Check if the gene symbol "AFG3L2" matches the protein description above** 2. **Verify the organism is correct:** Homo sapiens (Human). 3. **Check if protein family/domains align with what you find in literature** 4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP** ### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature: **DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead: - State clearly: "The gene symbol 'AFG3L2' is ambiguous or literature is limited for this specific protein" - Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism") - Describe the protein based ONLY on the UniProt information provided above - Suggest that the protein function can be inferred from domain/family information ### Research Target: Please provide a comprehensive research report on the gene **AFG3L2** (gene ID: AFG3L2, UniProt: Q9Y4W6) in human. The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims. You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway. We are interested in where in or outside the cell the gene product carries out its function. We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role. Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available. # Comprehensive Research Report: Human **AFG3L2** (UniProt **Q9Y4W6**) — Functional Annotation and Disease Relevance ## Executive summary AFG3L2 (UniProt Q9Y4W6) encodes a **mitochondrial inner membrane (IMM) m-AAA protease subunit** that assembles as **homo-hexamers** or **hetero-hexamers with SPG7/paraplegin**. The complex performs **ATP-dependent, zinc-metalloprotease proteolysis** (protein quality control and regulatory processing) with catalytic sites facing the **mitochondrial matrix**. Recent 2023–2024 literature substantially expanded the experimentally supported substrate set (e.g., **SLC25A39** for glutathione homeostasis; **MRPL32/bL32m** for mitoribosome assembly; **EMRE** for mitochondrial Ca2+ regulation) and connected AFG3L2 activity to **cell-state regulation**, including **hypoxia signaling via HIF1α–mTORC1** and **stress signaling via OMA1–DELE1–HRI integrated stress response (ISR)**. Pathogenic variants cause a spectrum from **dominant SCA28** and **dominant optic atrophy 12 (DOA12/OPA12)** to **recessive early-onset SPAX5**, with emerging preclinical therapeutic strategies centered on ISR tuning (e.g., **Sephin-1**) in SPAX5 models. (franchino2024sustainedoma1mediatedintegrated pages 1-2, dastidar2024multifacetedrolesof pages 1-2, liu2023autoregulatorycontrolof pages 3-4, chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) ## 1) Gene/protein identity verification (mandatory) The gene symbol **AFG3L2** in the recent literature matches the UniProt-defined target **Q9Y4W6**: a **mitochondrial inner membrane m-AAA protease component** with **AAA+ ATPase and zinc metalloprotease activities**, assembling into **m-AAA protease complexes** (homo-oligomeric AFG3L2 or hetero-oligomeric AFG3L2–SPG7). These defining characteristics are repeatedly stated in 2023–2024 review and primary sources. (franchino2024sustainedoma1mediatedintegrated pages 1-2, dastidar2024multifacetedrolesof pages 1-2, dastidar2024multifacetedrolesof pages 2-5, khalimonchuk2023moleculardeterminantsof pages 6-8) ## 2) Key concepts and definitions (current understanding) ### 2.1 m-AAA protease and mitochondrial proteostasis **m-AAA proteases** are IMM-embedded ATP-dependent protease complexes that provide **protein quality control (PQC)** by selective removal/processing of **non-assembled** or **damaged** mitochondrial proteins, thereby supporting inner membrane integrity and organelle function. AFG3L2-containing m-AAA is explicitly described as a **core component of IMM quality control** mediating selective degradation. (franchino2024sustainedoma1mediatedintegrated pages 1-2) ### 2.2 Domain logic and catalytic mechanism (AAA+ ATPase + Zn metalloprotease) AFG3L2 is functionally defined by: - an **AAA+ ATPase module** that uses ATP hydrolysis to **engage, unfold, and translocate** substrates through the central pore of the hexamer; and - a **C-terminal zinc metalloprotease domain** that cleaves substrates after translocation. A 2024 review describes ATP-stabilized hexamer assembly and a mechanistic sequence: substrate recruitment, ATP-dependent pore-loop engagement/translocation, followed by cleavage at a Zn-associated protease site. (dastidar2024multifacetedrolesof pages 1-2, dastidar2024multifacetedrolesof pages 2-5) ### 2.3 Subcellular localization and topology AFG3L2 localizes to the **mitochondrial inner membrane** with catalytic faces oriented to the **matrix** (matrix-facing AAA+ and proteolytic sites). (franchino2024sustainedoma1mediatedintegrated pages 1-2, khalimonchuk2023moleculardeterminantsof pages 6-8, chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5) ## 3) Primary molecular function: reaction, substrate specificity, and pathways ### 3.1 Primary biochemical function AFG3L2’s primary function is **ATP-dependent proteolysis** (metalloprotease EC 3.4.24.- class in UniProt terms) of specific mitochondrial substrates and misfolded/damaged IMM-associated proteins, coupled to **ATP-dependent unfolding/translocation** by its AAA+ motor. This is not a passive “housekeeping” role: multiple studies support **regulatory substrate processing/degradation** that tunes mitochondrial metabolism, Ca2+ transport, and gene expression. (franchino2024sustainedoma1mediatedintegrated pages 1-2, dastidar2024multifacetedrolesof pages 2-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5) ### 3.2 Experimentally supported substrates (high-confidence examples) #### 3.2.1 **SLC25A39** (mitochondrial glutathione transporter) — metabolic feedback control (2023) A 2023 Science paper establishes a direct functional axis in which **AFG3L2 degrades SLC25A39** under physiological conditions. Key quantitative data: - SLC25A39 has an estimated half-life of **~15 minutes** at baseline. - Mitochondrial glutathione (GSH) depletion stabilizes SLC25A39 to **>300 minutes**. - Glutathione supplementation restores rapid degradation. A CRISPR screen of mitochondrial peptidases identified **AFG3L2 as the only significant hit** controlling this regulation, supporting substrate specificity and a compartmentalized feedback loop for **mitochondrial GSH homeostasis**. (liu2023autoregulatorycontrolof pages 3-4) #### 3.2.2 **MRPL32 / bL32m** (mitoribosome biogenesis) Recent sources describe m-AAA/AFG3L2 as supporting **mitochondrial ribosome assembly** via processing/biogenesis of the ribosomal subunit **bL32m (MRPL32)**. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, khalimonchuk2023moleculardeterminantsof pages 6-8) #### 3.2.3 **EMRE** (MCU regulator) — mitochondrial Ca2+ handling AFG3L2/m-AAA is connected to maturation/turnover of **EMRE**, a regulatory component of the **mitochondrial calcium uniporter**. This links AFG3L2 proteolysis to **mitochondrial Ca2+ uptake control**. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, khalimonchuk2023moleculardeterminantsof pages 6-8) #### 3.2.4 **TIMMDC1** (Complex I assembly factor) A 2024 preprint reports **TIMMDC1** as an AFG3L2 substrate whose degradation links AFG3L2 to **complex I assembly control** and OXPHOS remodeling. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 5-9) #### 3.2.5 **TMBIM5/GHITM** (Ca2+/H+ homeostasis; inhibitor-substrate duality) In hypoxia-linked remodeling, **TMBIM5 (GHITM)** is described as both a **substrate** and an **inhibitor/modulator** of AFG3L2, implying feedback regulation that connects protease activity to mitochondrial ion homeostasis. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16) #### 3.2.6 Expanded substrate landscape in hypoxia: RNA metabolism and biogenesis factors (2024) Proteomic evidence under hypoxia suggests AFG3L2 targets numerous factors involved in mitochondrial gene expression and RNA granules, including **LRPPRC, SLIRP, MTPAP, POLRMT, TFB2M, DHX30, GRSF1**, as well as import factors (**PAM16, DNAJC15, TIMM17A**). These data support a model where AFG3L2 proteolysis can **restrict mitochondrial biogenesis and gene expression** under defined signaling conditions rather than only clearing misfolded proteins. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16) ## 4) Recent developments and latest research (prioritize 2023–2024) ### 4.1 2023: AFG3L2 couples glutathione availability to transporter turnover The Liu et al. (Science, Nov 2023) study is a major mechanistic advance: it defines a concrete, quantitative, **metabolite-coupled protease–transporter feedback loop** in mitochondria, where GSH levels gate AFG3L2-mediated degradation of SLC25A39. This provides a molecular explanation for how mitochondria can regulate a key metabolite transporter post-translationally. Publication date: **Nov 2023**. URL: https://doi.org/10.1126/science.adf4154 (liu2023autoregulatorycontrolof pages 3-4) ### 4.2 2024: Disease mechanism and therapy concept in SPAX5 — ISR as protective output Franchino et al. (Brain, Oct 2024) connect AFG3L2 deficiency to: - accumulation of mitochondria-encoded proteins and mitochondrial proteotoxicity, - **OMA1 overactivation** with **OPA1 over-processing** and mitochondrial fragmentation, and - activation of the **OMA1–DELE1–HRI ISR** (elevated eIF2α phosphorylation; increased ATF4; upregulation of targets including **Chop, Chac1, Ppp1r15a, Fgf21**). Importantly, they show **pharmacologic potentiation of ISR via Sephin-1** improves growth of SPAX5 fibroblasts, improves Purkinje neuron survival/arborization ex vivo, and **extends lifespan and improves cerebellar/mitochondrial phenotypes** in Afg3l2−/− mice—supporting ISR modulation as a plausible therapeutic direction. Publication date: **Oct 2024**. URL: https://doi.org/10.1093/brain/awad340 (franchino2024sustainedoma1mediatedintegrated pages 1-2) ### 4.3 2024: Hypoxia signaling connects AFG3L2 to control of mitochondrial biogenesis and gene expression A 2024 preprint reports that AFG3L2 proteolysis is activated in hypoxia along a **HIF1α–mTORC1 axis**; regulation is primarily **post-translational** (activity changes without requiring increased AFG3L2 abundance). Quantitative scope: proteomics suggests **dozens** of candidate substrates, including **38 proteins reduced** with amino-acid starvation and **72 proteins decreased in hypoxia** in an AFG3L2-dependent manner. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) This work further positions AFG3L2 as a regulated node in mitochondrial remodeling rather than a purely constitutive PQC enzyme. Publication date: **Sep 2024** (bioRxiv). URL: https://doi.org/10.1101/2024.09.27.615438 (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) ## 5) Current applications and real-world implementations ### 5.1 Clinical genetics and diagnostics AFG3L2 is implemented clinically primarily through **molecular genetic testing** for hereditary ataxia and optic neuropathy. A 2024 diagnostic classification review notes that for **SCA28**, **>99%** of reported cases are due to **SNVs or small intragenic deletions/insertions** (with copy-number changes reported as extremely rare), guiding practical test selection (sequencing prioritized; CNV assessment secondary). (lopergolo2024autosomalrecessivecerebellar pages 4-5) Reviews emphasize that multigene panels and/or clinical exome sequencing support diagnosis, particularly when common ataxia causes are excluded. (dastidar2024multifacetedrolesof pages 15-16, dastidar2024multifacetedrolesof pages 10-11) ### 5.2 Preclinical therapeutic strategies with translational logic - **ISR tuning as therapy (SPAX5):** Sephin-1 improved multiple cellular and organismal endpoints in Afg3l2 deficiency models, providing a concrete lead for future translational development and defining potential pharmacodynamic biomarkers (eIF2α phosphorylation; ATF4 targets). (franchino2024sustainedoma1mediatedintegrated pages 1-2) - **Supportive care remains standard for SCA28:** reviews indicate no disease-modifying therapy currently; management is supportive and rehabilitative. (dastidar2024multifacetedrolesof pages 15-16) ### 5.3 Biomarkers and mechanistic readouts A 2024 Brain study provides a coherent biomarker axis in patient fibroblasts and mouse cerebellum: increased eIF2α phosphorylation, ATF4, and downstream targets including **CHOP/CHAC1/PPP1R15A/FGF21** in SPAX5 contexts. These may serve as candidate biomarkers for patient stratification or monitoring in future interventions targeting the ISR. (franchino2024sustainedoma1mediatedintegrated pages 1-2) ## 6) Human phenotypes and genotype–phenotype mapping (current 2024 view) ### 6.1 Dominant **SCA28** (MIM#610246) SCA28 is described as a **slowly progressive** cerebellar ataxia, typically with oculomotor abnormalities; heterozygous pathogenic variants are a primary genetic cause. (dastidar2024multifacetedrolesof pages 15-16, franchino2024sustainedoma1mediatedintegrated pages 1-2) ### 6.2 Dominant optic neuropathy: **DOA12/OPA12** (MIM#618977) Heterozygous variants (notably in ATPase/catalytic domains) are linked to **dominant optic atrophy 12**, and may overlap with additional ocular/mitochondrial phenotypes depending on variant and genetic context. (dastidar2024multifacetedrolesof pages 15-16, franchino2024sustainedoma1mediatedintegrated pages 1-2) ### 6.3 Recessive early-onset spastic ataxia-neuropathy: **SPAX5 / spastic ataxia type 5** Biallelic loss-of-function variants cause a severe childhood-onset neurodegenerative disorder including cerebellar ataxia, spasticity, dystonia, neuropathy, and potentially myoclonic epilepsy. (dastidar2024multifacetedrolesof pages 15-16, franchino2024sustainedoma1mediatedintegrated pages 1-2) ## 7) Expert opinion / analysis (authoritative perspectives grounded in evidence) 1. **AFG3L2 is increasingly viewed as a regulated remodeling protease**, not merely a constitutive “garbage disposal.” Evidence includes stress- and nutrient-state regulation (HIF1α–mTORC1 axis) with broad substrate turnover shifts under hypoxia. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) 2. **Distinct mechanistic “modules” connect AFG3L2 dysfunction to disease**: - proteotoxic stress → OMA1 activation → OPA1 processing → mitochondrial fragmentation → ISR activation, with ISR shown to be beneficial when pharmacologically potentiated in SPAX5 models. (franchino2024sustainedoma1mediatedintegrated pages 1-2) - metabolite sensing/feedback → GSH-dependent control of SLC25A39 abundance, linking AFG3L2 to redox and Fe–S-linked metabolism. (liu2023autoregulatorycontrolof pages 3-4) Together these suggest that therapeutic strategies may need to be tailored to the dominant mechanistic axis in a given genotype/phenotype (e.g., ISR modulation for SPAX5-like biallelic loss; metabolic/proteostasis stabilization approaches for other contexts). (liu2023autoregulatorycontrolof pages 3-4, franchino2024sustainedoma1mediatedintegrated pages 1-2) ## 8) Relevant statistics and quantitative data (from recent studies) - **SLC25A39 protein half-life**: ~**15 min** at baseline; stabilized to **>300 min** under mitochondrial GSH depletion (MitoCHAC1 strategy) and rapidly degraded upon GSH supplementation, implicating AFG3L2-mediated control. (Nov 2023; https://doi.org/10.1126/science.adf4154) (liu2023autoregulatorycontrolof pages 3-4) - **Scale of AFG3L2-dependent proteome remodeling in hypoxia**: proteomics reported **38 proteins reduced** with amino-acid starvation and **72 proteins decreased in hypoxia** in an AFG3L2-dependent manner, emphasizing broad but enriched targeting of mitochondrial gene-expression machinery and related pathways. (Sep 2024; https://doi.org/10.1101/2024.09.27.615438) (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) - **Genetic variant-type distribution for SCA28**: a 2024 diagnostic review table reports **>99%** of reported SCA28 cases involve **SNVs/small intragenic indels**, with monoallelic deletion/duplication described as extremely rare, informing testing strategy. (Feb 2024; https://doi.org/10.3389/fnint.2023.1275794) (lopergolo2024autosomalrecessivecerebellar pages 4-5) ## 9) Evidence map (structured summary) The following table consolidates the main functional and translational points (complex identity, substrates, regulation, diseases) with DOI URLs. | Category | Specific detail | Evidence type (review/primary) | Key recent citation(s) with year + DOI URL | |---|---|---|---| | Protein/complex | **AFG3L2 = human mitochondrial inner-membrane m-AAA protease subunit** (UniProt Q9Y4W6); assembles as **homo-hexamers** or **hetero-hexamers with SPG7/paraplegin** to form the matrix-facing m-AAA protease complex (franchino2024sustainedoma1mediatedintegrated pages 1-2, dastidar2024multifacetedrolesof pages 1-2, dastidar2024multifacetedrolesof pages 2-5) | Review + primary | Dastidar et al., 2024, *Mol Neurobiol*, https://doi.org/10.1007/s12035-023-03768-z; Franchino et al., 2024, *Brain*, https://doi.org/10.1093/brain/awad340 | | Localization/topology | **Inner mitochondrial membrane (IMM)**, catalytic sites/AAA+ module **facing the matrix**; IM-anchored metalloprotease involved in protein quality control and mitochondrial biogenesis (franchino2024sustainedoma1mediatedintegrated pages 1-2, khalimonchuk2023moleculardeterminantsof pages 6-8, chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5) | Review + primary | Khalimonchuk & Becker, 2023, *Antioxid Redox Signal*, https://doi.org/10.1089/ars.2022.0124; Franchino et al., 2024, *Brain*, https://doi.org/10.1093/brain/awad340 | | Catalytic activities | Dual function: **AAA+ ATPase/unfoldase-translocase** plus **zinc metalloprotease**; ATP-driven substrate engagement/translocation feeds substrates to a C-terminal Zn-dependent protease site (dastidar2024multifacetedrolesof pages 1-2, dastidar2024multifacetedrolesof pages 2-5, khalimonchuk2023moleculardeterminantsof pages 6-8) | Review | Dastidar et al., 2024, *Mol Neurobiol*, https://doi.org/10.1007/s12035-023-03768-z; Khalimonchuk & Becker, 2023, *Antioxid Redox Signal*, https://doi.org/10.1089/ars.2022.0124 | | Substrate: SLC25A39 | **SLC25A39 glutathione transporter** is an experimentally supported AFG3L2 substrate; mitochondrial GSH depletion stabilizes SLC25A39 by reducing AFG3L2-dependent turnover, whereas GSH supplementation restores rapid degradation (liu2023autoregulatorycontrolof pages 3-4, chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 5-9) | Primary + review | Liu et al., 2023, *Science*, https://doi.org/10.1126/science.adf4154; Chandragiri et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.09.27.615438 | | Substrate: MRPL32 / bL32m | AFG3L2/m-AAA supports **biogenesis/processing of mitochondrial ribosomal bL32m (MRPL32)**, linking proteolysis to mitochondrial ribosome assembly and protein synthesis (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, dastidar2024multifacetedrolesof pages 7-9, khalimonchuk2023moleculardeterminantsof pages 6-8) | Review + primary | Khalimonchuk & Becker, 2023, *Antioxid Redox Signal*, https://doi.org/10.1089/ars.2022.0124; Chandragiri et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.09.27.615438 | | Substrate: EMRE | AFG3L2/m-AAA contributes to **EMRE maturation/turnover**, thereby regulating the mitochondrial calcium uniporter machinery and mitochondrial Ca²⁺ handling (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, dastidar2024multifacetedrolesof pages 7-9, khalimonchuk2023moleculardeterminantsof pages 6-8) | Review + primary | Khalimonchuk & Becker, 2023, *Antioxid Redox Signal*, https://doi.org/10.1089/ars.2022.0124; Chandragiri et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.09.27.615438 | | Substrate: TIMMDC1 | **TIMMDC1**, a complex I assembly factor, is degraded by AFG3L2, linking m-AAA proteolysis to respiratory-chain assembly control (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 5-9) | Primary | Chandragiri et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.09.27.615438 | | Substrate/regulator: TMBIM5 (GHITM) | **TMBIM5/GHITM** is both an **AFG3L2 substrate** and an **inhibitor/modulator** of AFG3L2, connecting the protease to mitochondrial Ca²⁺/H⁺ homeostasis and stress adaptation (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16) | Primary | Chandragiri et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.09.27.615438 | | Substrates: RNA metabolism factors | Recent proteomics identified AFG3L2 substrates in **mitochondrial RNA metabolism/gene expression**, including **LRPPRC, SLIRP, MTPAP, POLRMT, TFB2M, DHX30, GRSF1**, plus import factors (**PAM16, DNAJC15, TIMM17A**), especially under hypoxia (chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16, chandragiri2024afg3l2mediatedproteolysisrestricts pages 5-9, chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) | Primary | Chandragiri et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.09.27.615438 | | Regulatory pathway: GSH-dependent dissociation | **Mitochondrial glutathione status regulates AFG3L2–SLC25A39 interaction**: low matrix GSH promotes SLC25A39 stabilization by diminishing AFG3L2-mediated degradation, forming an autoregulatory feedback loop for mitochondrial GSH import (liu2023autoregulatorycontrolof pages 3-4) | Primary | Liu et al., 2023, *Science*, https://doi.org/10.1126/science.adf4154 | | Regulatory pathway: Hypoxia / HIF1α–mTORC1 | AFG3L2 proteolysis is **activated in hypoxia** along a **HIF1α–mTORC1 axis**; mTORC1 inhibition or amino-acid starvation increases turnover of multiple AFG3L2 substrates, whereas constitutive mTORC1 activity stabilizes them (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16, chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) | Primary | Chandragiri et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.09.27.615438 | | Regulatory pathway: PHB scaffold | The **prohibitin (PHB) membrane scaffold complex** associates with m-AAA protease and can modulate **substrate-specific AFG3L2 activity**, including in hypoxic remodeling of the mitochondrial proteome (chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16) | Primary | Chandragiri et al., 2024, *bioRxiv*, https://doi.org/10.1101/2024.09.27.615438 | | Regulatory pathway: OMA1–DELE1–HRI ISR | In AFG3L2 deficiency/mutation, **mitochondrial proteotoxic stress** causes **OMA1 overactivation**, excessive **OPA1 processing**, mitochondrial fragmentation, and activation of the **OMA1–DELE1–HRI integrated stress response (ISR)** with increased eIF2α phosphorylation and ATF4 signaling (franchino2024sustainedoma1mediatedintegrated pages 1-2) | Primary | Franchino et al., 2024, *Brain*, https://doi.org/10.1093/brain/awad340 | | Human disease: SCA28 | **Spinocerebellar ataxia type 28 (SCA28)**: typically **autosomal dominant**, usually from **heterozygous AFG3L2 variants**, characterized by slowly progressive gait/limb ataxia with frequent oculomotor abnormalities (dastidar2024multifacetedrolesof pages 15-16, dastidar2024multifacetedrolesof pages 10-11, lopergolo2024autosomalrecessivecerebellar pages 4-5, franchino2024sustainedoma1mediatedintegrated pages 1-2) | Review + primary | Franchino et al., 2024, *Brain*, https://doi.org/10.1093/brain/awad340; Dastidar et al., 2024, *Mol Neurobiol*, https://doi.org/10.1007/s12035-023-03768-z | | Human disease: DOA12 / OPA12 | **Dominant optic atrophy 12 (DOA12/OPA12)**: generally **autosomal dominant**, associated especially with **heterozygous ATPase- or catalytic-domain variants**; may overlap with ophthalmoplegia and broader mitochondrial optic neuropathy phenotypes (dastidar2024multifacetedrolesof pages 15-16, dastidar2024multifacetedrolesof pages 13-15, franchino2024sustainedoma1mediatedintegrated pages 1-2) | Review + primary | Franchino et al., 2024, *Brain*, https://doi.org/10.1093/brain/awad340; Dastidar et al., 2024, *Mol Neurobiol*, https://doi.org/10.1007/s12035-023-03768-z | | Human disease: SPAX5 | **Spastic ataxia type 5 / early-onset spastic ataxia-neuropathy syndrome (SPAX5)**: **autosomal recessive**, caused by **biallelic AFG3L2 variants**; severe childhood-onset phenotype with cerebellar ataxia, spasticity, dystonia, neuropathy, and in some cases myoclonic epilepsy (dastidar2024multifacetedrolesof pages 15-16, lopergolo2024autosomalrecessivecerebellar pages 4-5, dastidar2024multifacetedrolesof pages 13-15, franchino2024sustainedoma1mediatedintegrated pages 1-2) | Review + primary | Franchino et al., 2024, *Brain*, https://doi.org/10.1093/brain/awad340; Dastidar et al., 2024, *Mol Neurobiol*, https://doi.org/10.1007/s12035-023-03768-z | | Therapeutic/diagnostic implications | Current clinical use is mainly **genetic diagnosis/variant interpretation** (NGS panels, exome-based workup for ataxia/optic neuropathy). Preclinical 2024 evidence suggests **ISR potentiation with Sephin-1** can improve SPAX5 cellular and mouse phenotypes; molecular readouts include **eIF2α phosphorylation, ATF4 targets, CHOP/CHAC1/FGF21** (dastidar2024multifacetedrolesof pages 15-16, dastidar2024multifacetedrolesof pages 10-11, franchino2024sustainedoma1mediatedintegrated pages 1-2) | Review + primary | Franchino et al., 2024, *Brain*, https://doi.org/10.1093/brain/awad340; Dastidar et al., 2024, *Mol Neurobiol*, https://doi.org/10.1007/s12035-023-03768-z | *Table: This table condenses the core functional annotation of human AFG3L2, including complex identity, localization, catalytic mechanism, experimentally supported substrates, regulatory pathways, and associated human diseases. It is useful as a quick-reference map linking molecular function to disease relevance and recent literature.* ## 10) Limitations of the current evidence base (important for annotation quality) - Some mechanistic claims in the 2024 hypoxia study are from a **bioRxiv preprint** and therefore not yet peer-reviewed; the results are still useful as “latest research” but should be treated cautiously until validated. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5, chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) - AFG3L2-disease epidemiology (penetrance, population prevalence of SCA28/DOA12/SPAX5 specifically) was not directly available in the retrieved 2023–2024 sources; the report therefore focuses on mechanistic and diagnostic implementation evidence rather than attempting unsupported prevalence estimates. (dastidar2024multifacetedrolesof pages 15-16, lopergolo2024autosomalrecessivecerebellar pages 4-5) ## Key recent sources (URLs + publication timing) - Liu et al., **Science**, **Nov 2023**: https://doi.org/10.1126/science.adf4154 (liu2023autoregulatorycontrolof pages 3-4) - Khalimonchuk & Becker, **Antioxidants & Redox Signaling**, **May 2023**: https://doi.org/10.1089/ars.2022.0124 (khalimonchuk2023moleculardeterminantsof pages 6-8) - Franchino et al., **Brain**, **Oct 2024**: https://doi.org/10.1093/brain/awad340 (franchino2024sustainedoma1mediatedintegrated pages 1-2) - Dastidar et al., **Molecular Neurobiology**, **2024 (online; issue cites Nov 2024)**: https://doi.org/10.1007/s12035-023-03768-z (dastidar2024multifacetedrolesof pages 1-2) - Chandragiri et al., **bioRxiv preprint**, **Sep 2024**: https://doi.org/10.1101/2024.09.27.615438 (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13) - Lopergolo et al., **Frontiers in Integrative Neuroscience**, **Feb 2024**: https://doi.org/10.3389/fnint.2023.1275794 (lopergolo2024autosomalrecessivecerebellar pages 4-5) References 1. (franchino2024sustainedoma1mediatedintegrated pages 1-2): Camilla Aurora Franchino, Martina Brughera, Valentina Baderna, Daniele De Ritis, Alessandra Rocco, Sara Seneca, Luc Regal, Paola Podini, Maurizio D’Antonio, Camilo Toro, Angelo Quattrini, Emmanuel Scalais, and Francesca Maltecca. Sustained oma1-mediated integrated stress response is beneficial for spastic ataxia type 5. Brain, 147:1043-1056, Oct 2024. URL: https://doi.org/10.1093/brain/awad340, doi:10.1093/brain/awad340. This article has 19 citations and is from a highest quality peer-reviewed journal. 2. (dastidar2024multifacetedrolesof pages 1-2): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal. 3. (liu2023autoregulatorycontrolof pages 3-4): Yuyang Liu, Shanshan Liu, Anju Tomar, Frederick S. Yen, Gokhan Unlu, Nathalie Ropek, Ross A. Weber, Ying Wang, Artem Khan, Mark Gad, Junhui Peng, Erdem Terzi, Hanan Alwaseem, Alexandra E. Pagano, Søren Heissel, Henrik Molina, Benjamin Allwein, Timothy C. Kenny, Richard L. Possemato, Li Zhao, Richard K. Hite, Ekaterina V. Vinogradova, Sheref S. Mansy, and Kıvanç Birsoy. Autoregulatory control of mitochondrial glutathione homeostasis. Nov 2023. URL: https://doi.org/10.1126/science.adf4154, doi:10.1126/science.adf4154. This article has 126 citations and is from a highest quality peer-reviewed journal. 4. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 9-13): Srikanth Chandragiri, Nils Grotehans, Yvonne Lasarzewski, Maria Patron, Thomas MacVicar, Yohsuke Ohba, Steffen Hermans, Elena Rugarli, Hendrik Nolte, and Thomas Langer. Afg3l2-mediated proteolysis restricts mitochondrial biogenesis and gene expression in hypoxia. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615438, doi:10.1101/2024.09.27.615438. This article has 2 citations. 5. (dastidar2024multifacetedrolesof pages 2-5): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal. 6. (khalimonchuk2023moleculardeterminantsof pages 6-8): Oleh Khalimonchuk and Donald F. Becker. Molecular determinants of mitochondrial shape and function and their role in glaucoma. Antioxidants & Redox Signaling, 38:896-919, May 2023. URL: https://doi.org/10.1089/ars.2022.0124, doi:10.1089/ars.2022.0124. This article has 7 citations and is from a domain leading peer-reviewed journal. 7. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 1-5): Srikanth Chandragiri, Nils Grotehans, Yvonne Lasarzewski, Maria Patron, Thomas MacVicar, Yohsuke Ohba, Steffen Hermans, Elena Rugarli, Hendrik Nolte, and Thomas Langer. Afg3l2-mediated proteolysis restricts mitochondrial biogenesis and gene expression in hypoxia. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615438, doi:10.1101/2024.09.27.615438. This article has 2 citations. 8. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 5-9): Srikanth Chandragiri, Nils Grotehans, Yvonne Lasarzewski, Maria Patron, Thomas MacVicar, Yohsuke Ohba, Steffen Hermans, Elena Rugarli, Hendrik Nolte, and Thomas Langer. Afg3l2-mediated proteolysis restricts mitochondrial biogenesis and gene expression in hypoxia. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615438, doi:10.1101/2024.09.27.615438. This article has 2 citations. 9. (chandragiri2024afg3l2mediatedproteolysisrestricts pages 13-16): Srikanth Chandragiri, Nils Grotehans, Yvonne Lasarzewski, Maria Patron, Thomas MacVicar, Yohsuke Ohba, Steffen Hermans, Elena Rugarli, Hendrik Nolte, and Thomas Langer. Afg3l2-mediated proteolysis restricts mitochondrial biogenesis and gene expression in hypoxia. bioRxiv, Sep 2024. URL: https://doi.org/10.1101/2024.09.27.615438, doi:10.1101/2024.09.27.615438. This article has 2 citations. 10. (lopergolo2024autosomalrecessivecerebellar pages 4-5): Diego Lopergolo, Francesca Rosini, Elena Pretegiani, Alessia Bargagli, Valeria Serchi, and Alessandra Rufa. Autosomal recessive cerebellar ataxias: a diagnostic classification approach according to ocular features. Frontiers in Integrative Neuroscience, Feb 2024. URL: https://doi.org/10.3389/fnint.2023.1275794, doi:10.3389/fnint.2023.1275794. This article has 10 citations. 11. (dastidar2024multifacetedrolesof pages 15-16): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal. 12. (dastidar2024multifacetedrolesof pages 10-11): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal. 13. (dastidar2024multifacetedrolesof pages 7-9): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal. 14. (dastidar2024multifacetedrolesof pages 13-15): Ranita Ghosh Dastidar, Saradindu Banerjee, Piyush Behari Lal, and Somasish Ghosh Dastidar. Multifaceted roles of afg3l2, a mitochondrial atpase in relation to neurological disorders. Molecular Neurobiology, 61:3788-3808, Nov 2024. URL: https://doi.org/10.1007/s12035-023-03768-z, doi:10.1007/s12035-023-03768-z. This article has 19 citations and is from a peer-reviewed journal. ## Artifacts - [Edison artifact artifact-00](AFG3L2-deep-research-falcon_artifacts/artifact-00.md) ## Citations 1. liu2023autoregulatorycontrolof pages 3-4 2. lopergolo2024autosomalrecessivecerebellar pages 4-5 3. dastidar2024multifacetedrolesof pages 15-16 4. khalimonchuk2023moleculardeterminantsof pages 6-8 5. dastidar2024multifacetedrolesof pages 1-2 6. dastidar2024multifacetedrolesof pages 2-5 7. dastidar2024multifacetedrolesof pages 10-11 8. dastidar2024multifacetedrolesof pages 7-9 9. dastidar2024multifacetedrolesof pages 13-15 10. https://doi.org/10.1126/science.adf4154 11. https://doi.org/10.1093/brain/awad340 12. https://doi.org/10.1101/2024.09.27.615438 13. https://doi.org/10.3389/fnint.2023.1275794 14. https://doi.org/10.1007/s12035-023-03768-z; 15. https://doi.org/10.1089/ars.2022.0124; 16. https://doi.org/10.1089/ars.2022.0124 17. https://doi.org/10.1126/science.adf4154; 18. https://doi.org/10.1093/brain/awad340; 19. https://doi.org/10.1007/s12035-023-03768-z 20. https://doi.org/10.1093/brain/awad340, 21. https://doi.org/10.1007/s12035-023-03768-z, 22. https://doi.org/10.1126/science.adf4154, 23. https://doi.org/10.1101/2024.09.27.615438, 24. https://doi.org/10.1089/ars.2022.0124, 25. https://doi.org/10.3389/fnint.2023.1275794,